Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway

Table 7 Base case results, Norway

	Cost components (EUR)
	Treatment costs	GP/A&E visits	Hospital	Triptan treatment	Total direct costs
*Botox*	7751	3177	1549	819	13,297
*Placebo*	2439	3457	1723	906	8524
	Total and incremental results
	Total costs (EUR)	Discounted Total costs (EUR)	Incremental cost	Total QALYs	Discounted QALYs	Incremental QALYs	ICER
*Botox*	13,297	11,501	4301	6.503	5.480	0.216	19,954
*Placebo*	8524	7200	4301	6.255	5.264	0.216	19,954

Key: A&E Accident and emergency; GP General practitioner; ICER Incremental cost-effectiveness ratio; QALY Quality adjusted life years. Note: Treatment costs include the administration cost for Botox and the neurologist visits for both Botox and placebo

ISSN: 1129-2377